Neuropathic pain due to chronic idiopathic axonal neuropathy: fast pain reduction after topical phenytoin cream application

<p>Pain due to chronic idiopathic axonal polyneuropathy (CIAP) is often treated with therapies based on general neuropathic pain guidelines, which are mainly developed with randomized clinical trials having valuated treatments for painful diabetic neuropathy (PDN) and post-herpetic neuralgia....

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Jan M Keppel Hesselink (Autor), David J Kopsky (Autor)
Format: Książka
Wydane: Open Journal of Pain Medicine - Peertechz Publications, 2018-11-15.
Hasła przedmiotowe:
Dostęp online:Connect to this object online.
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_ojpm_000008
042 |a dc 
100 1 0 |a Jan M Keppel Hesselink  |e author 
700 1 0 |a David J Kopsky  |e author 
245 0 0 |a Neuropathic pain due to chronic idiopathic axonal neuropathy: fast pain reduction after topical phenytoin cream application 
260 |b Open Journal of Pain Medicine - Peertechz Publications,   |c 2018-11-15. 
520 |a <p>Pain due to chronic idiopathic axonal polyneuropathy (CIAP) is often treated with therapies based on general neuropathic pain guidelines, which are mainly developed with randomized clinical trials having valuated treatments for painful diabetic neuropathy (PDN) and post-herpetic neuralgia. No clinical trial studying treatments for patients with painful CIAP has been yet executed, thus only extrapolation of the value of treatments from other neuropathic pain fi elds is possible. Clearly, the pathogenesis and pathophysiology of CIAP will be quite different from that of PDN. Many CIAP patients complain of intolerable side effects of current analgesic medication. In order to help those patients, we developed a treatment-regime consisting of the supplement palmitoylethanolamide and topical formulations of analgesics. This combination is rarely complicated by side effects. One of our most recent topical formulation we developed contains 10% phenytoin, a broad acting voltage-gated sodium-channel blocker. Phenytoin 10% cream can also be used as a stand-alone therapy as we will discuss.</p> 
540 |a Copyright © Jan M Keppel Hesselink et al. 
546 |a en 
655 7 |a Research Article  |2 local 
856 4 1 |u https://doi.org/10.17352/ojpm.000008  |z Connect to this object online.